![synergy pharmaceuticals synergy pharmaceuticals](https://www.cure4herpes.com/wp-content/uploads/2018/09/Synergy-Combination-Products.jpg)
- #SYNERGY PHARMACEUTICALS PROFESSIONAL#
- #SYNERGY PHARMACEUTICALS SERIES#
- #SYNERGY PHARMACEUTICALS FREE#
In episodic therapy, the patient starts taking their prescribed medication at the first sign of an outbreak. The medications are then used in one of two therapeutic approaches. Standard protocol involves one of three types of FDA-approved antiviral medications – acyclovir, valacyclovir, or famciclovir. This treatment stands in stark contrast to standard herpes treatment protocols.
![synergy pharmaceuticals synergy pharmaceuticals](https://www.synergy-pharmaceuticals.com/wp-content/uploads/Synergy-Pharmaceutical-Logo.png)
![synergy pharmaceuticals synergy pharmaceuticals](https://www.pharmabizconnect.com/uploads/packshots/70b665deafa958b8009ea5e6804a4116.jpg)
For the best outcome, patients are instructed to take 1-2 pills of each, every morning for 4-6 months. The five components of Synergy Pharmaceuticals’ Combination Herpes Treatment are L-Lysine, Tribulus, Astragalus, Rhodiola, and a Unique Amino Formula. There was no noticeable improvement after taking the single-ingredient treatment, but 80% of patients were herpes-free after a few months of the five-ingredient treatment. The patients were tested for the IgG herpes antibody after taking a single natural ingredient and after taking five natural ingredients.
#SYNERGY PHARMACEUTICALS SERIES#
Roger’s results were verified in a series of clinical tests involving randomly selected herpes patients. Synergy Pharmaceuticals Introduc e s th e Product Against the Herpes Virus
![synergy pharmaceuticals synergy pharmaceuticals](https://i1.sndcdn.com/artworks-tDKkbzDw1jS1POdQ-8pGf9w-t500x500.jpg)
So, why haven’t more professionals supported it? Finally, after years and years of stumbles, false starts, and ethical crises, the medical industry had a cure for herpes. He passed his findings on to officials at New York City-based biopharmaceutical company Synergy Pharmaceuticals, who conducted clinical trials and confirmed that the right holistic treatment could indeed cure herpes. But, determined to overcome the virus, he formulated a combination of natural ingredients that gradually reduced his outbreaks and then completely removed the virus from his bloodstream. He was convinced his life was permanently altered and he fell into a depressive state. He was intentionally infected with HSV-2 and suffered several painful outbreaks each year. During 2011, Roger was one of those patients. 16, 2021 (GLOBE NEWSWIRE) - Synergy Pharmaceuticals is proud to introduce its product against herpes, as nearly 800,000 people are newly infected with herpes each year. Vonage shares surged on the news and by 1100 GMT were trading up 28% in pre-market trade at $20.95.Melbourne, Australia, Aug. Then back it with Vonage’s advanced capabilities, in a world of 8 billion connected devices. "Imagine putting the power and capabilities of 5G, the biggest global innovation platform, at the fingertips of developers. Vonage gives us a platform to help our customers monetize the investments in the network, benefitting developers and businesses. The acquisition of Vonage is the next step in delivering on that strategic priority. This provides the foundation to build an enterprise business. The company’s president and chief executive, Börje Ekholm, said: "The core of our strategy is to build leading mobile networks through technology leadership.
#SYNERGY PHARMACEUTICALS FREE#
It also expects to achieve some cost efficiencies following completion of the transaction, which is set to be accretive to earnings per share and free cash flow before M&A from 2024 onwards. It said "the transaction builds upon Ericsson’s stated intent to expand globally in wireless enterprise, offering existing customers an increased share of a market valued at $700bn by 2030".Įricsson said the deal is expected to deliver near-term revenue synergy opportunities, including white-labelling and cross-selling of the combined product portfolio estimated to contribute $0.4bn by 2025. Under the terms of the acquisition, Ericsson will pay $21 per share. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds.Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so.
#SYNERGY PHARMACEUTICALS PROFESSIONAL#
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body.Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services.Obtains access to the information in a personal capacity.I am a private investor* I am not a private investor *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: